BiotechTube

sepofarsen

Phase 2/3Active
0 watching 0 views this week⚡ Active
57
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Leber Congenital Amaurosis 10

Conditions

Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders, Sensation Disorders, Neurologic Manifestations, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease

Trial Timeline

Apr 4, 2019 → Mar 1, 2023

NCT ID
NCT03913143

About sepofarsen

sepofarsen is a phase 2/3 stage product being developed by ProQR for Leber Congenital Amaurosis 10. The current trial status is active. This product is registered under clinical trial identifier NCT03913143. Target conditions include Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis.

Hype Score Breakdown

Clinical
22
Activity
15
Company
2
Novelty
7
Community
8

Clinical Trials (2)

NCT IDPhaseStatus
NCT04855045Phase 2/3UNKNOWN
NCT03913143Phase 2/3Active

Competing Products

12 competing products in Leber Congenital Amaurosis 10

See all competitors
ProductCompanyStageHype Score
EDIT-101Editas MedicinePhase 1/2
33
AAV RPE65MeiraGTxPhase 1/2
33
AAV OPTIRPE65MeiraGTxPre-clinical
15
Idebenone + PlaceboSanthera PharmaceuticalsPhase 2
44
IdebenoneSanthera PharmaceuticalsApproved
77
Idebenone 150 MG Oral TabletSanthera PharmaceuticalsPre-clinical
15
IdebenoneSanthera PharmaceuticalsPre-clinical
15
sepofarsenProQRPhase 2/3
57
Idebenone + PlaceboSanthera PharmaceuticalsPhase 3
69
GS010GenSight BiologicsPhase 3
69
GS010GenSight BiologicsPhase 3
69
PlaceboGenSight BiologicsPhase 3
69

Other Products from ProQR

sepofarsenPhase 2/3
57
QR-1123Phase 1/2
33
QR-421aPhase 1/2
33
QR-010 + PlaceboPhase 1/2
33
QR-504aPhase 1
25